FDA releases draft guidance on oversight of individualized gene-editing products

The U.S. Food and Drug Administration issued draft guidance that outlines a proposed regulatory framework for individualized gene‑editing products, including cases where multiple product variants are developed under a single investigational new drug application.

The guidance is intended to close a regulatory gap for these bespoke therapies, describing how the agency will assess safety and efficacy when each patient may receive a unique version of a gene‑editing treatment.

Commissioner Kyle Diamantas used the announcement to underscore the FDA’s broader push to modernize rare‑disease development and embed the patient voice, referencing the new rare‑disease framework discussed at the NORD Breakthrough Summit.